Verteporfin Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Verteporfin comprises 52 peer-reviewed publications across 15 journals, 7 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Macular Degeneration, Cicatrix, Pancreatic Neoplasms, and Choroidal Neovascularization. Most recent publication: Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis., Jpn J Ophthalmol, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. EUS-guided verteporfin photodynamic therapy for pancreatic cancer.
    Hanada Y, Pereira SP, Pogue B, et al. · Gastrointest Endosc · 2021
    PubMed: PMID 33647286 · NCT03033225 · Pancreatic Neoplasms
  2. Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis.
    Yanagi Y, Mori R, Teo KYC, et al. · Jpn J Ophthalmol · 2025
    PubMed: PMID 40504425 · NCT01846273 (EVEREST II) · Macular Degeneration
  3. CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment.
    Vincent P, Maeder ME, Hunt B, et al. · Phys Med Biol · 2021
    PubMed: PMID 34261044 · NCT03033225 · Pancreatic Neoplasms
  4. Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study.
    Teo KYC, Park KH, Ngah NF, et al. · Ophthalmol Ther · 2024
    PubMed: PMID 38308746 · NCT01846273 (EVEREST II) · Macular Degeneration
  5. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
    Lim TH, Lai TYY, Takahashi K, et al. · JAMA Ophthalmol · 2021
    PubMed: PMID 32672800 · NCT01846273 (EVEREST II) · Macular Degeneration
  6. Interventions for central serous chorioretinopathy: a network meta-analysis.
    Lange CA, Qureshi R, Pauleikhoff L, et al. · Cochrane Database Syst Rev · 2025
    PubMed: PMID 40522203 · NCT01019668 · Central Serous Chorioretinopathy
  7. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
    Lai K, Li Y, Zhou L, et al. · BMC Ophthalmol · 2018
    PubMed: PMID 29925341 · NCT03459144 · Polypoidal Choroidal Vasculopathy
  8. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A, Lai TYY, Takahashi K, et al. · JAMA Ophthalmol · 2017
    PubMed: PMID 28983556 · NCT01846273 (EVEREST II) · Macular Degeneration

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00242580
VERITAS
Macular DegenerationPercentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline.
Baseline to Month 12
Verteporfin + 1 mg Triamcinolone59.4 Percentage of Participants
Verteporfin + 4 mg Triamcinolone63.4 Percentage of Participants
Verteporfin + Pegaptanib71.1 Percentage of Participants
NCT00433017Macular DegenerationChange From Baseline in Best-corrected Visual Acuity (BCVA) at Month 12.
Baseline and Month 12
Ranibizumab4.4 Letters (±15.92 Standard Deviation)
Ranibizumab55.1 Letters (±12.3 Standard Deviation)
Ranibizumab59.4 Letters (±18.8 Standard Deviation)
Verteporfin + Ranibizumab54.6 Letters (±13.5 Standard Deviation)
Verteporfin + Ranibizumab2.5 Letters (±14.82 Standard Deviation)
Verteporfin + Ranibizumab57.1 Letters (±18.3 Standard Deviation)
NCT00433017Macular DegenerationPercent of Participants With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit
Month 2 to Month 11
Ranibizumab92.2 Percentage of Participants
Verteporfin + Ranibizumab95.8 Percentage of Participants
NCT00436553Macular DegenerationMean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12
Baseline and Month 12
Ranibizumab Monotherapy63.0 Letters (±18.88 Standard Deviation)
Ranibizumab Monotherapy8.1 Letters (±15.09 Standard Deviation)
Ranibizumab Monotherapy54.8 Letters (±13.55 Standard Deviation)
Verteporfin RF + Ranibizumab4.4 Letters (±15.47 Standard Deviation)
Verteporfin RF + Ranibizumab59.0 Letters (±18.03 Standard Deviation)
Verteporfin RF + Ranibizumab54.6 Letters (±12.78 Standard Deviation)
Verteporfin SF + Ranibizumab5.3 Letters (±15.66 Standard Deviation)
Verteporfin SF + Ranibizumab53.7 Letters (±13.52 Standard Deviation)
Verteporfin SF + Ranibizumab59.0 Letters (±17.47 Standard Deviation)
NCT00436553Macular DegenerationPercent of Patients With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit
Month 2 up to Month 11
Verteporfin RF + Ranibizumab83.5 Percent of participants
Verteporfin SF + Ranibizumab92.6 Percent of participants
NCT01217944Choroidal NeovascularizationAverage Change From Baseline to Month 1 Through Month 3 on Visual Acuity of the Study Eye
Baseline, Month 1 through Month 3
0.5 mg Ranibizumab Driven by Stabilization Criteria55.4 Letters (±13.43 Standard Deviation)
0.5 mg Ranibizumab Driven by Stabilization Criteria66.0 Letters (±12.98 Standard Deviation)
0.5mg Ranibizumab Driven by Disease Activity66.4 Letters (±12.28 Standard Deviation)
0.5mg Ranibizumab Driven by Disease Activity55.8 Letters (±12.59 Standard Deviation)
Verteporfin PDT56.9 Letters (±14.49 Standard Deviation)
Verteporfin PDT54.7 Letters (±13.84 Standard Deviation)
NCT01922102
Brilliance
Choroidal NeovascularizationChange From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3
From Baseline to Month 3
Group I53.7 ETDRS letters (±12.65 Standard Deviation)
Group I63.1 ETDRS letters (±12.80 Standard Deviation)
Group II54.2 ETDRS letters (±13.01 Standard Deviation)
Group II63.9 ETDRS letters (±13.28 Standard Deviation)
Group III52.6 ETDRS letters (±12.29 Standard Deviation)
Group III57.1 ETDRS letters (±13.21 Standard Deviation)

Publications by year

1991–2025: 52 publications.

1991
1
1996
1
2000
1
2001
1
2002
2
2003
2
2004
2
2005
4
2006
7
2011
1
2012
4
2013
2
2014
2
2015
3
2017
2
2018
1
2019
3
2020
1
2021
4
2022
3
2024
2
2025
3

Publications by indication

Macular Degeneration (25)

  • Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis.
    Jpn J Ophthalmol · 2025 · PMID 40504425 · NCT01846273
  • Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study.
    Ophthalmol Ther · 2024 · PMID 38308746 · NCT01846273
  • Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
    JAMA Ophthalmol · 2021 · PMID 32672800 · NCT01846273
  • Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    JAMA Ophthalmol · 2017 · PMID 28983556 · NCT01846273
  • EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy.
    Br J Ophthalmol · 2015 · PMID 25758601 · NCT00674323

Cicatrix (18)

  • Inhibiting mechanotransduction prevents scarring and yields regeneration in a large animal model.
    Sci Transl Med · 2025 · PMID 39970235 · NCT07488988
  • The Impact of Acne, Atopic Dermatitis, Skin Toxicities and Scars on Quality of Life and the Importance of a Holistic Treatment Approach.
    Clin Cosmet Investig Dermatol · 2024 · PMID 34163201 · NCT07488988
  • Converting fibroblastic fates leads to wound healing without scar.
    Signal Transduct Target Ther · 2022 · PMID 34471094 · NCT06944249
  • Reduction of Cardiac Fibrosis by Interference With YAP-Dependent Transactivation.
    Circ Res · 2022 · PMID 35770662 · NCT07488988
  • Targeted inhibition of YAP/TAZ alters the biological behaviours of keloid fibroblasts.
    Exp Dermatol · 2022 · PMID 34623712 · NCT07488988

Pancreatic Neoplasms (2)

  • EUS-guided verteporfin photodynamic therapy for pancreatic cancer.
    Gastrointest Endosc · 2021 · PMID 33647286 · NCT03033225
  • CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment.
    Phys Med Biol · 2021 · PMID 34261044 · NCT03033225

Choroidal Neovascularization (2)

  • Visual acuity outcome in RADIANCE study patients with dome-shaped macular features.
    Ophthalmology · 2015 · PMID 25109929 · NCT01217944
  • RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.
    Ophthalmology · 2014 · PMID 24326106 · NCT01217944

Histoplasmosis (1)

  • Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis syndrome.
    Ophthalmic Surg Lasers Imaging Retina · 2013 · PMID 23410808 · NCT00546936

Central Serous Chorioretinopathy (1)

  • Interventions for central serous chorioretinopathy: a network meta-analysis.
    Cochrane Database Syst Rev · 2025 · PMID 40522203 · NCT01019668

Publications by journal

Trial-results highlights

Clinical trials have investigated Verteporfin, often in combination with other therapies, for conditions such as macular degeneration and choroidal neovascularization. In the VERITAS trial (NCT00242580) for macular degeneration, the primary outcome measured the percentage of participants who lost less than 15 letters of best corrected visual acuity (BCVA) at 12 months from baseline. The reported percentages were:

  • 59.4% of participants in the Verteporfin + 1 mg Triamcinolone arm.
  • 63.4% of participants in the Verteporfin + 4 mg Triamcinolone arm.
  • 71.1% of participants in the Verteporfin + Pegaptanib arm.

Further studies explored Verteporfin for macular degeneration. In NCT00433017, the change from baseline in BCVA at Month 12 was reported. For the Ranibizumab arm, mean BCVA values were 55.1 Letters at baseline, 59.4 Letters at Month 12, with a mean change from baseline of 4.4 Letters. For the Verteporfin + Ranibizumab arm, mean BCVA values were 54.6 Letters at baseline, 57.1 Letters at Month 12, with a mean change from baseline of 2.5 Letters. This trial also reported that 92.2% of participants in the Ranibizumab arm and 95.8% of participants in the Verteporfin + Ranibizumab arm had a treatment-free interval of at least 3 months following the Month

All Verteporfin publications (52)

2025 (3 papers)

  1. Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis.
    Yanagi Y, Mori R, Teo KYC, et al. · Jpn J Ophthalmol · 2025 · Derived
    PubMed: PMID 40504425 · NCT01846273 (EVEREST II) · Macular Degeneration
  2. Interventions for central serous chorioretinopathy: a network meta-analysis.
    Lange CA, Qureshi R, Pauleikhoff L, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 40522203 · NCT01019668 · Central Serous Chorioretinopathy
  3. Inhibiting mechanotransduction prevents scarring and yields regeneration in a large animal model.
    Mascharak S, Griffin M, Talbott HE, et al. · Sci Transl Med · 2025 · Background
    PubMed: PMID 39970235 · NCT07488988 (SCARFREE-001) · Cicatrix

2024 (2 papers)

  1. Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study.
    Teo KYC, Park KH, Ngah NF, et al. · Ophthalmol Ther · 2024 · Derived
    PubMed: PMID 38308746 · NCT01846273 (EVEREST II) · Macular Degeneration
  2. The Impact of Acne, Atopic Dermatitis, Skin Toxicities and Scars on Quality of Life and the Importance of a Holistic Treatment Approach.
    Dreno B, Amici JM, Demessant-Flavigny AL, et al. · Clin Cosmet Investig Dermatol · 2024 · Background
    PubMed: PMID 34163201 · NCT07488988 (SCARFREE-001) · Cicatrix

2022 (3 papers)

  1. Converting fibroblastic fates leads to wound healing without scar.
    Jiang D, Rinkevich Y · Signal Transduct Target Ther · 2022 · Background
    PubMed: PMID 34471094 · NCT06944249 · Cicatrix
  2. Reduction of Cardiac Fibrosis by Interference With YAP-Dependent Transactivation.
    Garoffolo G, Casaburo M, Amadeo F, et al. · Circ Res · 2022 · Background
    PubMed: PMID 35770662 · NCT07488988 (SCARFREE-001) · Cicatrix
  3. Targeted inhibition of YAP/TAZ alters the biological behaviours of keloid fibroblasts.
    Gao N, Lu L, Ma X, et al. · Exp Dermatol · 2022 · Background
    PubMed: PMID 34623712 · NCT07488988 (SCARFREE-001) · Cicatrix

2021 (4 papers)

  1. EUS-guided verteporfin photodynamic therapy for pancreatic cancer.
    Hanada Y, Pereira SP, Pogue B, et al. · Gastrointest Endosc · 2021 · Trial result
    PubMed: PMID 33647286 · NCT03033225 · Pancreatic Neoplasms
  2. CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment.
    Vincent P, Maeder ME, Hunt B, et al. · Phys Med Biol · 2021 · Derived
    PubMed: PMID 34261044 · NCT03033225 · Pancreatic Neoplasms
  3. Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
    Lim TH, Lai TYY, Takahashi K, et al. · JAMA Ophthalmol · 2021 · Derived
    PubMed: PMID 32672800 · NCT01846273 (EVEREST II) · Macular Degeneration
  4. Preventing Engrailed-1 activation in fibroblasts yields wound regeneration without scarring.
    Mascharak S, desJardins-Park HE, Davitt MF, et al. · Science · 2021 · Background
    PubMed: PMID 33888614 · NCT07488988 (SCARFREE-001) · Cicatrix

2020 (1 paper)

  1. Yap/Taz regulate alveolar regeneration and resolution of lung inflammation.
    LaCanna R, Liccardo D, Zhang P, et al. · J Clin Invest · 2020 · Background
    PubMed: PMID 30985294 · NCT07488988 (SCARFREE-001) · Cicatrix

2019 (3 papers)

  1. YAP/TAZ regulates TGF-β/Smad3 signaling by induction of Smad7 via AP-1 in human skin dermal fibroblasts.
    Qin Z, Xia W, Fisher GJ, et al. · Cell Commun Signal · 2019 · Background
    PubMed: PMID 29695252 · NCT07488988 (SCARFREE-001) · Cicatrix
  2. Hippo pathway coactivators Yap and Taz are required to coordinate mammalian liver regeneration.
    Lu L, Finegold MJ, Johnson RL, et al. · Exp Mol Med · 2019 · Background
    PubMed: PMID 29303509 · NCT07488988 (SCARFREE-001) · Cicatrix
  3. Two succeeding fibroblastic lineages drive dermal development and the transition from regeneration to scarring.
    Jiang D, Correa-Gallegos D, Christ S, et al. · Nat Cell Biol · 2019 · Background
    PubMed: PMID 29593327 · NCT06944249 · Cicatrix

2018 (1 paper)

  1. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
    Lai K, Li Y, Zhou L, et al. · BMC Ophthalmol · 2018 · Derived
    PubMed: PMID 29925341 · NCT03459144 · Polypoidal Choroidal Vasculopathy

2017 (2 papers)

  1. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A, Lai TYY, Takahashi K, et al. · JAMA Ophthalmol · 2017 · Derived
    PubMed: PMID 28983556 · NCT01846273 (EVEREST II) · Macular Degeneration
  2. MAPK-Mediated YAP Activation Controls Mechanical-Tension-Induced Pulmonary Alveolar Regeneration.
    Liu Z, Wu H, Jiang K, et al. · Cell Rep · 2017 · Background
    PubMed: PMID 27498861 · NCT07488988 (SCARFREE-001) · Cicatrix

2015 (3 papers)

  1. EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy.
    Tan CS, Ngo WK, Chen JP, et al. · Br J Ophthalmol · 2015 · Derived
    PubMed: PMID 25758601 · NCT00674323 (PCV) · Macular Degeneration
  2. Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy.
    Ritter M, Simader C, Bolz M, et al. · Br J Ophthalmol · 2015 · Derived
    PubMed: PMID 25079064 · NCT00433017 · Macular Degeneration
  3. Visual acuity outcome in RADIANCE study patients with dome-shaped macular features.
    Ceklic L, Wolf-Schnurrbusch U, Gekkieva M, et al. · Ophthalmology · 2015 · Derived
    PubMed: PMID 25109929 · NCT01217944 · Choroidal Neovascularization

2014 (2 papers)

  1. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.
    Wolf S, Balciuniene VJ, Laganovska G, et al. · Ophthalmology · 2014 · Derived
    PubMed: PMID 24326106 · NCT01217944 · Choroidal Neovascularization
  2. Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration.
    Grijalva JL, Huizenga M, Mueller K, et al. · Am J Physiol Gastrointest Liver Physiol · 2014 · Background
    PubMed: PMID 24875096 · NCT07488988 (SCARFREE-001) · Cicatrix

2013 (2 papers)

  1. Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis syndrome.
    Ramaiya KJ, Blinder KJ, Ciulla T, et al. · Ophthalmic Surg Lasers Imaging Retina · 2013 · Derived
    PubMed: PMID 23410808 · NCT00546936 · Histoplasmosis
  2. Hippo pathway effector Yap promotes cardiac regeneration.
    Xin M, Kim Y, Sutherland LB, et al. · Proc Natl Acad Sci U S A · 2013 · Background
    PubMed: PMID 23918388 · NCT07488988 (SCARFREE-001) · Cicatrix

2012 (4 papers)

  1. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
    Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. · Ophthalmology · 2012 · Derived
    PubMed: PMID 22424834 · NCT00433017 · Macular Degeneration
  2. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
    Koh A, Lee WK, Chen LJ, et al. · Retina · 2012 · Derived
    PubMed: PMID 22426346 · NCT00674323 (PCV) · Macular Degeneration
  3. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK, Boyer DS, Cruess AF, et al. · Ophthalmology · 2012 · Derived
    PubMed: PMID 22444829 · NCT00436553 · Macular Degeneration
  4. Scarless human fetal skin repair is intrinsic to the fetal fibroblast and occurs in the absence of an inflammatory response.
    Lin RY, Sullivan KM, Argenta PA, et al. · Wound Repair Regen · 2012 · Background
    PubMed: PMID 17147649 · NCT07488988 (SCARFREE-001) · Cicatrix

2011 (1 paper)

  1. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
    Bae SH, Heo JW, Kim C, et al. · Am J Ophthalmol · 2011 · Derived
    PubMed: PMID 21742303 · NCT01325181

2006 (7 papers)

  1. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, et al. · Ophthalmology · 2006 · Background
    PubMed: PMID 16647134 · NCT00390208 (PDEX) · Macular Degeneration
  2. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Spaide RF, Laud K, Fine HF, et al. · Retina · 2006 · Background
    PubMed: PMID 16603955 · NCT00390208 (PDEX) · Macular Degeneration
  3. Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin.
    Nicolò M, Ghiglione D, Lai S, et al. · Retina · 2006 · Background
    PubMed: PMID 16395140 · NCT00390208 (PDEX) · Macular Degeneration
  4. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment.
    Maturi RK, Bleau LA, Wilson DL, et al. · Retina · 2006 · Background
    PubMed: PMID 16508425 · NCT00390208 (PDEX) · Macular Degeneration
  5. Testing intravitreal toxicity of bevacizumab (Avastin).
    Manzano RP, Peyman GA, Khan P, et al. · Retina · 2006 · Background
    PubMed: PMID 16508423 · NCT00390208 (PDEX) · Macular Degeneration
  6. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL, Pieramici DJ, Rabena MD, et al. · Ophthalmology · 2006 · Background
    PubMed: PMID 16458968 · NCT00390208 (PDEX) · Macular Degeneration
  7. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration.
    Augustin AJ, Schmidt-Erfurth U · Am J Ophthalmol · 2006 · Background
    PubMed: PMID 16564797 · NCT00390208 (PDEX) · Macular Degeneration

2005 (4 papers)

  1. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina.
    Tamura H, Miyamoto K, Kiryu J, et al. · Invest Ophthalmol Vis Sci · 2005 · Background
    PubMed: PMID 15790913 · NCT00390208 (PDEX) · Macular Degeneration
  2. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.
    Spaide RF, Sorenson J, Maranan L, et al. · Ophthalmology · 2005 · Background
    PubMed: PMID 15691567 · NCT00390208 (PDEX) · Macular Degeneration
  3. Safety of verteporfin for treatment of subfoveal choroidal neovascular membranes associated with age-related macular degeneration.
    Gaynes BI, Fiscella RG · Expert Opin Drug Saf · 2005 · Background
    PubMed: PMID 15268651 · NCT07488988 (SCARFREE-001) · Cicatrix
  4. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown.
    Edelman JL, Lutz D, Castro MR, et al. · Exp Eye Res · 2005 · Background
    PubMed: PMID 15670803 · NCT00390208 (PDEX) · Macular Degeneration

2004 (2 papers)

  1. Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients.
    Bessler NM, Vam Study Writing Committee · Retina · 2004 · Background
    PubMed: PMID 15300071 · NCT07488988 (SCARFREE-001) · Cicatrix
  2. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4.
    Azab M, Benchaboune M, Blinder KJ, et al. · Retina · 2004 · Background
    PubMed: PMID 15076937 · NCT07488988 (SCARFREE-001) · Cicatrix

2003 (2 papers)

  1. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor.
    Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, et al. · Invest Ophthalmol Vis Sci · 2003 · Background
    PubMed: PMID 14507895 · NCT00390208 (PDEX) · Macular Degeneration
  2. Intravitreal dexamethasone effectively reduces postoperative inflammation after vitreoretinal surgery.
    Chalam KV, Malkani S, Shah VA, et al. · Ophthalmic Surg Lasers Imaging · 2003 · Background
    PubMed: PMID 12757090 · NCT00390208 (PDEX) · Macular Degeneration

2002 (2 papers)

  1. Clinical pharmacokinetics of verteporfin.
    Houle JM, Strong A · J Clin Pharmacol · 2002 · Background
    PubMed: PMID 12017349 · NCT07488988 (SCARFREE-001) · Cicatrix
  2. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM, Arnold J, Benchaboune M, et al. · Arch Ophthalmol · 2002 · Background
    PubMed: PMID 12427056 · NCT00390208 (PDEX) · Macular Degeneration

2001 (1 paper)

  1. Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor.
    Wenzel A, Grimm C, Seeliger MW, et al. · Invest Ophthalmol Vis Sci · 2001 · Background
    PubMed: PMID 11381074 · NCT00390208 (PDEX) · Macular Degeneration

2000 (1 paper)

  1. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis.
    Shah GK, Stein JD, Sharma S, et al. · Ophthalmology · 2000 · Background
    PubMed: PMID 10711885 · NCT00390208 (PDEX) · Macular Degeneration

1996 (1 paper)

  1. Light-emitting diodes as a light source for intraoperative photodynamic therapy.
    Schmidt MH, Bajic DM, Reichert KW, et al. · Neurosurgery · 1996 · Background
    PubMed: PMID 8837808 · NCT00002647 · Glioblastoma

1991 (1 paper)

  1. Evaluation of a single intravitreal injection of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications.
    Blankenship GW · Graefes Arch Clin Exp Ophthalmol · 1991 · Background
    PubMed: PMID 2004725 · NCT00390208 (PDEX) · Macular Degeneration

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).